The tumor microenvironment (TME) dictates the outcome of cancer immunotherapy. In this issue of Cell Chemical Biology, Yu et al.¹ report that targeting Mettl3 leads to a more inflamed, “hot” TME and effective anti-PD-1 therapy. This study points to a new target in remodeling the TME for improved immunotherapy.

中文翻译：

---

METTL3：融化肿瘤微环境以改善免疫治疗

肿瘤微环境（TME）决定了癌症免疫治疗的结果。在本期《细胞化学生物学》中，Yu 等人。^{1 号}报告指出，针对Mettl3会导致炎症加剧、“热”TME 和有效的抗 PD-1 疗法。这项研究指出了重塑 TME 以改善免疫治疗的新目标。